STEVEN IDELL
Medical Practice in Tyler, TX
License number
Pennsylvania MD021887E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Tyler, TX 75703
Pennsylvania
Pennsylvania
Personal information
See more information about STEVEN IDELL at radaris.comName
Address
Phone
1001 Cedar St, Bonham, TX 75418
4614 Arapahoe Trl, Austin, TX 78745
1810 Easy St, Tyler, TX 75703
4614 Arapahoe Trl, Austin, TX 78745
1282 County Road 2005, Ivanhoe, TX 75447
Professional information
See more information about STEVEN IDELL at trustoria.com
Dr. Steven Idell, Tyler TX - MD (Doctor of Medicine)
Dr. Steven Idell, Tyler TX - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
University Texas Health Scien Center
11937 Us Highway 271, Tyler 75708
(903) 877-3451 (Phone)
11937 Us Highway 271, Tyler 75708
(903) 877-3451 (Phone)
Certifications:
Critical Care Medicine, 1987, Internal Medicine, 1980, Pulmonary Disease, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
University Texas Health Scien Center
11937 Us Highway 271, Tyler 75708
University of Texas Health Center at Tyler
11937 Us Highway 271, Tyler 75708
11937 Us Highway 271, Tyler 75708
University of Texas Health Center at Tyler
11937 Us Highway 271, Tyler 75708
Education:
Medical School
Temple University School Of Medicine
Graduated: 1977
Temple Hospital
Graduated: 1978
Graduated: 1980
Graduated: 1983
Temple University School Of Medicine
Graduated: 1977
Temple Hospital
Graduated: 1978
Graduated: 1980
Graduated: 1983
Steven Idell, Tyler TX
Steven Idell, Tyler TX
Specialties:
Pulmonologist
Address:
11937 Us Highway 271, Tyler, TX 75708
Education:
Temple University - Doctor of Philosophy*
Temple University, School of Medicine - Doctor of Medicine*
Temple University Hospital - Fellowship - Pulmonary Disease (Internal Medicine)*
Temple University Hospital - Residency - Internal Medicine*
Temple University, School of Medicine - Doctor of Medicine*
Temple University Hospital - Fellowship - Pulmonary Disease (Internal Medicine)*
Temple University Hospital - Residency - Internal Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)*
Steven Idell, Tyler TX
Steven Idell, Tyler TX
Work:
University of Texas Health Center Tyler
11937 Us Highway 271, Tyler, TX 75708
11937 Us Highway 271, Tyler, TX 75708
Peptide Inhibition Of Lung Epithelial Apoptosis And Pulmonary Fibrosis
Peptide Inhibition Of Lung Epithelial Apoptosis And Pulmonary Fibrosis
US Patent:
2009022, Sep 10, 2009
Filed:
Mar 5, 2009
Appl. No.:
12/398757
Inventors:
Sreerama Shetty - Tyler TX, US
Steven Idell - Tyler TX, US
Steven Idell - Tyler TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 38/00, C07K 7/00, A61K 38/10
US Classification:
514 13, 530326, 530300, 514 2
Abstract:
During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed. The peptides and functional variants, peptide multimers, cell-targeted polyepeptides and pharmaceutical compositions are used in methods for inhibiting apoptosis of injured or damaged lung epithelial cells and for treating acute lung injury and consequent pulmonary fibrosis.
Intrapleural Single-Chain Urokinase Alone Or Complexed To Its Soluble Receptor Protects Against Pleural Adhesions
Intrapleural Single-Chain Urokinase Alone Or Complexed To Its Soluble Receptor Protects Against Pleural Adhesions
US Patent:
2003021, Nov 27, 2003
Filed:
Apr 4, 2003
Appl. No.:
10/407821
Inventors:
Steven Idell - Tyler TX, US
Assignee:
Board of Regents, The University of Texas System
International Classification:
A61L009/04, A61K038/46
US Classification:
424/045000, 424/094650
Abstract:
The present invention relates to methods of preventing or decreasing the severity of scarring in a subject comprising: obtaining a pharmaceutical composition comprising a single chain urokinase plasminogen activator molecule (scuPA) or a scuPA mimetic; and administering the pharmaceutical composition to a subject; wherein scarring in the subject is either prevented or decreased relative to an amount of scarring that would be expected if the pharmaceutical composition were not administered to the subject. The invention also relates to methods of screening for compounds that prevent or decrease the severity of scarring in a subject.
Regulation Of Urokinase Receptor Expression By Phosphoglycerate Kinase
Regulation Of Urokinase Receptor Expression By Phosphoglycerate Kinase
US Patent:
2005004, Mar 3, 2005
Filed:
Jul 2, 2004
Appl. No.:
10/884195
Inventors:
Sreerama Shetty - Tyler TX, US
Steven Idell - Tyler TX, US
Steven Idell - Tyler TX, US
International Classification:
A61K038/48
US Classification:
424094500
Abstract:
The present invention provides methods for treating inflammatory diseases, neoplastic diseases, wound healing and preventing scarring by administering a therapeutically effective amount of phosphoglycerate phosphokinase (PGK) peptide, polypeptide, protein, mutant or mimetic to a subject. The invention also relates to methods of screening for compounds for modulation of uPAR expression or activity. The present invention further provides coding sequences of phosphoglycerate kinase peptides, polypeptides, or proteins, or mutants, or mimetics thereof as a gene therapy for inflammatory diseases, cancer, wound healing, or tissue scarring.
Modified Fvii In Treatment Of Ards
Modified Fvii In Treatment Of Ards
US Patent:
2004003, Feb 19, 2004
Filed:
Oct 30, 2002
Appl. No.:
10/283482
Inventors:
Mirella Ezban - Kobenhavn K, DK
Claude Piantadosi - Durham NC, US
Steven Idell - Tyler TX, US
Claude Piantadosi - Durham NC, US
Steven Idell - Tyler TX, US
International Classification:
A61K038/39, A61L009/04
US Classification:
424/045000, 514/012000
Abstract:
The present invention relates to the use of modified factor VI[ for manufacture of medicaments for treatment of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) in humans.